Overview
- Application materials are available now, with applications due April 1, 2026 for the first performance period beginning July 1, 2026, and later submissions considered for a January 1, 2027 start.
- ACCESS will use Outcome-Aligned Payments that provide recurring revenue only when cohort-level health targets are met, and CMS plans track-specific G-codes while barring fee-for-service claims for enrolled patients during the performance period.
- Participants must be Medicare Part B–enrolled organizations that designate a clinical director, manage care using technology-enabled services across four tracks (eCKM, CKM, MSK, BH), and meet rigorous API-based data reporting requirements; DME suppliers and clinical laboratories are excluded.
- The FDA’s TEMPO pilot tied to ACCESS is collecting manufacturer statements of interest starting around January 2, 2026, expects to select up to 10 U.S. manufacturers in each use area, and will request additional information beginning around March 2, 2026.
- New features include direct beneficiary enrollment, an option to waive patient cost-sharing for ACCESS payments, and a separate co-management payment for primary care clinicians, while HHS is taking AI-in-clinical-care comments through February 23, 2026.